Medesis Pharma S.A. (EPA:ALMDP)

France flag France · Delayed Price · Currency is EUR
0.3500
0.00 (0.00%)
Inactive · Last trade price on May 14, 2025
Market Cap1.77M
Revenue (ttm)63.64K
Net Income (ttm)-3.13M
Shares Out5.06M
EPS (ttm)-0.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Openn/a
Previous Close0.3500
Day's Rangen/a
52-Week Range0.3000 - 2.0000
Beta0.18
RSI40.91
Earnings DateApr 17, 2025

About United States Steel

Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 10
Stock Exchange Euronext Paris
Ticker Symbol ALMDP
Full Company Profile

Financial Performance

In 2023, Medesis Pharma's revenue was 300,034, an increase of 52.07% compared to the previous year's 197,297. Losses were -3.96 million, 44.0% more than in 2022.

Financial Statements

News

There is no news available yet.